Alnylam reports positive Phase II immunoglobulin A nephropathy data
In the trial, cemdisiran offered a 37% mean decline from baseline in the 24-hour urine protein to creatinine ratio versus…
Neurology
Latest in
Neurology
Pipeline Moves: Eledon’s advancement shot in ALS reviewed after Phase IIa data reveal
The Clinical Trials Arena team also dig into benign tumours, hepatitis B, lymphomas, myelofibrosis, polycythemia vera, and soft tissue sarcoma.
By
Tranquis Therapeutics concludes Phase I ALS treatment trial
In the trial, single and multiple doses of TQS-168 demonstrated to be well tolerated in 78 healthy subjects.
Alterity initiates Phase II multiple system atrophy therapy trial
The double-blind, placebo-controlled, randomised trial will analyse ATH434 in subjects with early-stage MSA.
Biogen, Denali begin Phase IIb trial of Parkinson’s disease therapy
The trial will analyse the safety and efficacy of BIIB122 in nearly 640 Parkinson’s patients aged between 30 and 80…
Kintara activates first European site of Phase II/III glioblastoma trial
The GBM AGILE trial is currently underway at 44 clinical centres in the US and Canada.
Biohaven’s zavegepant nasal spray set to reach projected worth of $206.8m in 2030
If approved, zavegepant will be the first and only intranasal treatment for migraine in the gepant drug class.
By
Clario and Cogstate to offer data quality solutions for neuroscience trials
Clario’s eCOA Multimedia technology will be merged with clinical network and expertise of Cogstate in neurodegenerative ailments.